
[Cancer Research 60, 5214-5222, September 15, 2000]
© 2000 American Association for Cancer Research
Experimental Therapeutics |
MT-21 Is a Synthetic Apoptosis Inducer That Directly Induces Cytochrome c Release from Mitochondria1
Masahiko Watabe,
Kiyotaka Machida and
Hiroyuki Osada2
Antibiotics Laboratory, Riken Institute, Hirosawa 2-1, Wako-shi, Saitama 351-0198, Japan
 |
ABSTRACT
|
|---|
We reported previously that a synthetic compound, MT-21, induced
apoptosis by activating c-Jun-NH2-terminal kinase via the
Krs/MST protein, which is activated by caspase-3 cleavage dependent on
reactive oxygen species production. Here we examine the activation
mechanism of caspase-3, an important cysteine aspartic protease, during
MT-21-induced apoptosis. We found that MT-21 activated caspase-3 via
caspase-9, but not via caspase-8. In addition, MT-21 induced the
release of cytochrome c from the mitochondria that is
necessary to activate caspase-9, and this release occurred before a
change in membrane potential. This initiation process of MT-21-induced
apoptosis was suppressed by overexpression of Bcl-2, which is known to
prevent cells from undergoing apoptosis in response to a variety of
stimuli. Moreover, when we treated mitochondria isolated from the cells
with MT-21, the direct release of cytochrome c from the
mitochondria was observed, whereas this effect was not observed in the
mitochondria isolated from cells that overexpressed Bcl-2. Other
apoptosis-inducing agents known to induce apoptosis via cytochrome
c release from the mitochondria failed to release
cytochrome c directly from isolated mitochondria. These
findings indicate that MT-21 is a possible candidate antitumor agent
that is able to induce apoptosis via the direct release of cytochrome
c from the mitochondria.
 |
INTRODUCTION
|
|---|
Apoptosis-inducing compounds are possible candidate antitumor
agents. Recent advances have led to a widely accepted model that a
conserved family of cysteine proteases (caspases) plays important roles
in apoptosis (1)
. Caspases themselves are present as
proenzymes that are readily cleaved and activated during apoptosis,
providing the cell with a means to rapidly amplify its apoptotic
response (2)
. In addition, the similar proteolytic cascade
was induced, and consequent morphological changes occurred during
apoptosis, irrespective of the type of stimuli.
There are various pathways leading to the caspase cascade, depending on
the apoptotic stimuli. For example, apoptosis caused by activation of
the CD95/Fas receptors is brought about by recruitment of the adaptor
protein Fas-associated protein with death domain (3)
.
Fas-associated protein with death domain, in turn, recruits
procaspase-8 via a homophilic interaction between the death effector
domains of these proteins, and this event is followed by autocatalytic
cleavage and activation of the clustered procaspase (4
, 5)
. In contrast, activation of caspase-9 by apoptotic stimuli
proceeds via recruitment of the procaspase to a signaling complex
containing apoptotic protease-activating factor 1 and cytochrome
c (6, 7, 8)
, which is believed to be released from
the mitochondria as an early event in several models of apoptosis
(9)
. Cytochrome c is encoded by a nuclear gene
and translated by cytosolic ribosomes as apocytochrome c
(10)
. Apocytochrome c is subsequently
translocated into the mitochondria, where a heme group is attached
covalently to form holocytochrome c (10)
. The
increase in cytosolic holocytochrome c on apoptosis suggests
that mitochondria may participate in apoptosis by releasing cytochrome
c. Based on the finding that both caspase-8
(11)
and caspase-9 (6)
cleave and activate
caspase-3 in cell-free assays of apoptosis, it is widely believed that
these initiator caspases lie at the apex of separate apoptotic cascades
that converge on activation of downstream effector caspases.
Recently, we found that MT-21, a synthetic compound, induced apoptosis
in human promyelocytic leukemia HL-60 cells and activated
JNK3
by activation of a Mr 36,000
kinase termed p36 MBP kinase via caspase-3 activation during
MT-21- induced apoptosis (12)
. In addition, p36 MBP kinase
is an active proteolytic product of Krs-1 and Krs-2, which were
originally cloned by virtue of their homology to the budding yeast
Ste20 kinase (12, 13, 14, 15)
. Furthermore, cytotrienin A,
a novel ansamycin antitumor agent that we isolated from
Streptomyces sp. as an apoptosis inducer (16
, 17)
, also generated the proteolytically activated Krs protein
p36 MBP kinase mediated by caspase-3 during apoptosis
(15)
. Recently, two other groups (18
, 19)
reported that Krs-2 is cleaved by a caspase-3-like activity during
apoptosis induced by Fas (CD95/APO-1). In the present study, we reveal
that most known antitumor agents indirectly induce cytochrome
c release from the mitochondria and that MT-21 directly
induces cytochrome c release and activates the caspase
cascade during apoptosis.
 |
MATERIALS AND METHODS
|
|---|
Chemicals.
MT compounds were synthesized as described previously
(20)
. Z-IETD-FMK and Z-LEHD-FMK were purchased from Kamiya
Biomedical Company (Seattle, WA) and are caspase-8 and caspase-9
inhibitors, respectively. Anti-caspase-3 antibody was obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), anti-cytochrome
c antibody was obtained from PharMingen (San Diego,
CA), and anti-Bcl-2 antibody was obtained from DAKO (Kyoto, Japan).
Cells.
Human promyelocytic leukemia HL-60 and U937 cells were cultured in RPMI
1640 supplemented with 10% FCS at 37°C in a 5%
CO2 humidified atmosphere.
Analysis of DNA Fragmentation by Agarose Gel Electrophoresis.
HL-60 cells were lysed with a solution consisting of 10 mM
Tris-HCl (pH 8.0), 10 mM EDTA, 0.5% (w/v) SDS, and 0.1%
(w/v) RNase A and incubated for 60 min at 50°C. The lysate was
incubated for an additional 60 min at 50°C with 1 mg/ml proteinase K,
and phenol/chloroform-extracted DNA was electrophoresed on a 2% (w/v)
agarose gel in 40 mM Tris-acetate (pH 7.5) containing 1
mM EDTA for 90 min at 50 V. After electrophoresis, DNA was
visualized by ethidium bromide staining.
Preparation of Cell Lysate.
HL-60 cells were lysed with 0.1 ml of lysis buffer consisting of 10
mM Tris-HCl (pH 7.4), 1 mM EDTA, 1
mM EGTA, 0.15 M NaCl, 5 µg/ml aprotinin, 5
µg/ml leupeptin, 0.5 mM PMSF, 2 mM sodium
orthovanadate, and 1% (w/v) Triton X-100. The cell lysate was
centrifuged at 15,000 x g for 20 min. The
supernatant thus obtained was used for immunoblotting with an
anti-caspase-3 antibody and for measuring protein kinase activities.
Immunoblotting.
Cell lysates containing 20 µg of protein were subjected to SDS-PAGE
and separated. The proteins were then transferred to a
polyvinylidene difluoride membrane with a semidry blotting
apparatus at 2 mA/cm2 constant current for 1 h. The membrane was first washed with TBS and then blocked with 3%
(w/v) BSA in TBS for 1 h at room temperature. The blocked membrane
was subsequently probed for 1 h at room temperature with the
primary antibody diluted 1:1000 in TBS containing 0.1% (w/v) BSA.
After washing with TBS containing 0.1% (w/v) Tween 20 (TTBS), the
membrane was incubated for 1 h at room temperature with
horseradish peroxidase-conjugated secondary antibody diluted 1:2000 in
TBS containing 0.1% (w/v) BSA. After washing with TTBS, protein bands
on the membrane were visualized by an enhanced chemiluminescence
Western blotting detection system (DuPont New England Nuclear, Boston,
MA).
Cytochrome c Release from Mitochondria in
Drug-treated Cells.
Untreated and drug-treated cells were harvested by centrifugation at
1,000 x g for 5 min at 4°C. The cells
pellets were washed once with ice-cold PBS and resuspended with 5
volumes of 20 mM HEPES-KOH (pH 7.5), 10
mM KCl, 1.5 mM
MgCl2, 1 mM EDTA, 1
mM EGTA, 1 mM DTT, 0.1
mM PMSF, and 250 mM
sucrose. The cells were homogenized with a 22-gauge needle, and the
homogenates were centrifuged at 750 x g for
10 min at 4°C. The supernatants were then centrifuged at
10,000 x g for 15 min at 4°C. The pellets
were lysed with 0.1 ml of lysis buffer consisting of 10
mM Tris-HCl (pH 7.4), 1 mM
EDTA, 1 mM EGTA, 0.15 M
NaCl, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 0.5
mM PMSF, 2 mM sodium
orthovanadate, and 1% SDS. The lysed solution was used for the
identification of mitochondrial cytochrome c by
immunoblotting. The supernatants were centrifuged at 100,000 x g for 15 min at 4°C, and the obtained supernatants
were used for identification of cytosolic cytochrome c by
immunoblotting.
Cytochrome c Release from Mitochondria in a
Cell-free System.
Mitochondria were purified from the cells by differential
centrifugation and separation on a sucrose gradient (21)
.
Mitochondria were suspended with 20 µl of CFS [20 mM
HEPES-KOH (pH 7.5), 10 mM KCl, 1.5 mM
MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 0.1 mM PMSF, 5 mM
succinate, 1 mM ADP, and 250 mM sucrose], and
MT compounds were added. After a 2-h incubation at 37°C, this
suspension was centrifuged at 10,000 x g for
15 min at 4°C. The supernatants were used for identification of
cytochrome c release from mitochondria by immunoblotting.
Changes in Mitochondrial Transmembrane Potential
(
m).
To measure 
m, the cells were incubated with 10 µg/ml JC-1
(Molecular Probes, Eugene, OR) for 30 min in culture medium at 37°C.
The cells were washed once with PBS and analyzed immediately by flow
cytometry (Epics Elite; Coulter, Hialeah, FL). At least 50,000 events
were collected per sample.
Evaluation of Intracellular H2O2.
The cells were treated with chemicals in the presence of 5
µM dichlorodihydrofluorescein diacetate (DCFH-DA).
The esterified form of DCFH-DA can permeate cell membranes and
can then be deacetylated by intracellular esterases. The resulting
compound is reactive with
H2O2 to give a fluorescent
compound, dichlorofluorescein (12)
. The amount of
intracellular H2O2 was
detected by flow cytometry (Epics Elite; Coulter).
Immunofluorescence Microscopy.
Immunocytochemical study of cytochrome c was performed as
described previously (22)
. Cells treated with 40
µM MT-21 were washed once with PBS and then
fixed in PBS containing 3.7% formaldehyde for 5 min at room
temperature. Cells were then permeabilized with PBS containing 0.2%
Triton X-100 for 5 min and then washed three times with PBS. Incubation
with primary antibody (anti-cytochrome c at a 1:100
dilution) was carried out for 1 h at room temperature. Excess
antibody was removed by washing three times with PBS. This was followed
by incubation with an appropriate FITC-conjugated secondary antibody
for 1 h at room temperature in an area protected against light.
After excess antibody was removed by washing three times with PBS,
images were collected by fluorescence microscopy.
Detection of MBP Kinase Activity in SDS-Polyacrylamide Gel.
Separation gel containing 10% (w/v) polyacrylamide, 0.1% (w/v) SDS,
and 0.5 mg/ml MBP was prepared as described previously
(12)
, and 40 µg of protein of cell lysates were
subjected to electrophoresis. After electrophoresis, the gel was
incubated for 1 h in 50 mM Tris-HCl (pH 8.0)
containing 20% (v/v) isopropyl alcohol to remove SDS and then
incubated for 1 h in Buffer A consisting of 50
mM Tris-HCl (pH 8.0) and 5 mM
2-mercaptoethanol. Subsequently, proteins in the gel were denatured for
1 h in Buffer A containing 6 M guanidine-HCl. The
denatured proteins were renatured by incubating the gel for 12 h
at 4°C in four changes of Buffer A containing 0.05% (w/v) Tween 20.
The entire gel was then subjected to a kinase assay. After a 30-min
preincubation at room temperature in Buffer B [40 mM HEPES
(pH 7.5), 10 mM MgCl2, 2
mM DTT, and 0.1 mM EGTA], the gel was
incubated for 1 h in Buffer B containing 20 µM
[
-32P]ATP (25 µCi) at 30°C. The gel was
washed, extensively with a solution consisting of 5% (w/v)
trichloroacetic acid and 1% (w/v) sodium pyrophosphate, dried, and
subjected to autoradiography at -80°C using Kodak X-OMAT AR5 X-ray
film and an intensifying screen.
Determination of JNK Activity.
JNK activity in the whole cell extracts (0.1 mg) was measured by
incubation with 10 µg of glutathione
S-transferase-c-Jun179(179) conjugated to glutathione-agarose
beads [prepared according to the manufacturers instructions
(Pharmacia)] for 1 h at 4°C. The agarose beads were collected
by quick microcentrifugation and washed five times with HEPES binding
buffer [20 mM HEPES (pH 8.0), 20
mM MgCl2, 0.1
mM EDTA, 50 mM NaCl, and
0.05% Triton X-100]. The final wash was performed in kinase buffer
[20 mM HEPES (pH 8.0), 20
mM MgCl2, 20
mM ß-glycerophosphate, 0.1
mM sodium vanadate, and 2
mM DTT]. The kinase reaction was initiated by
resuspending the pelleted beads in 30 µl of kinase buffer containing
[
-32P]ATP (20 µM;
0.5 µCi/reaction) for 10 min at 30°C. The reaction was terminated
by the addition of 1 ml of ice-cold HEPES binding buffer. The beads
were pelleted, resuspended in SDS sample buffer, and boiled for 5 min.
Proteins were separated by electrophoresis on a 10% SDS-polyacrylamide
gel followed by autoradiography.
 |
RESULTS
|
|---|
Activation of Caspase-9 by MT-21.
The active form of caspase-3 consists of two subunits, p20 and p12, and
is derived from a precursor protein (p32) by proteolytic
processing. Therefore, the activation of caspase-3 by MT-21 is detected
as the decrease of the precursor form of caspase-3. To examine whether
the activation of caspase-3 induced by MT-21 was caused by caspase-8 or
-9, we performed immunoblotting with an anti-caspase-3 antibody using
each specific inhibitor against caspase-8 or -9. IETD, a
caspase-8-specific inhibitor, inhibited the activation of caspase-3
induced by tumor necrosis factor
, but not the activation induced by
MT-21 (Fig. 1A)
. We obtained the same result on the induction of a ladder
pattern typical of internucleosomal fragmentation, which is considered
to be an early event in apoptosis (Fig. 1B)
. On the other
hand, LEHD, a caspase-9-specific inhibitor, inhibited the activation of
caspase-3 and DNA fragmentation by MT-21 (Fig. 1, C and D)
. These results suggest that MT-21 activates caspase-3 via
caspase-9 activation during apoptosis.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 1. Activation of caspase-9 but not caspase-8 by MT-21 in
HL-60 cells. HL-60 cells were treated with 40 µM MT-21
for 6 h or with 50 ng/ml tumor necrosis factor for 16 h
in the absence or presence of 20 µM Z-IETD-FMK
(A and B) or 40 µM
Z-LEHD-FMK (C and D). Immunoblotting
analysis was performed using anti-caspase-3 antibodies
(A and C). Cellular DNA extracted from
the cells was analyzed by agarose gel electrophoresis and stained with
ethidium bromide (B and D).
|
|
Release of Cytochrome c from Mitochondria Induced by
MT-21.
Because caspase-9 is activated by complex formation with apoptotic
protease-activating factor 1 and cytochrome c, we examined
the effect of MT- 21 on the release of cytochrome c from
mitochondria. Without MT-21 treatment, most of the detectable
cytochrome c was localized on mitochondria in the cells
(Fig. 2A)
. Cytochrome c in the cytosol of the cells
increased significantly after 3 h of treatment with MT-21 (Fig. 2B)
. The amounts of cytochrome c in mitochondria
showed a corresponding decrease. In our previous report, MT-21 caused
the production of ROS before apoptosis induction, and NAC, a scavenger
of H2O2, suppressed
MT-21-induced apoptosis (12)
. Therefore, we tested the
effect of antioxidants on MT-21-induced release of cytochrome
c from mitochondria. As shown in Fig. 2C
, the
increase of cytochrome c in the cytosol induced by MT-21 was
suppressed by NAC but not by NAS, a negative control of NAC. These
results indicated that MT-21 induced the release of cytochrome
c from mitochondria via ROS production during apoptosis.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2. Release of cytochrome c from mitochondria
by MT-21. HL-60 cells were treated with 40 µM MT-21 for
the indicated time periods. After preparation of the cytosolic or
mitochondrial fraction, immunoblotting analysis was performed using
anti-cytochrome c antibodies (A and
B). C, HL-60 cells were pretreated with 3
mM NAC and 3 mM NAS and then treated with 40
µM MT-21 for 6 h. After preparation of the cytosolic
fraction, immunoblotting analysis was performed as described in
A.
|
|
Release of Cytochrome c Occurs before the Loss of

m.
Because some observations have suggested that the change in 
m is
major cause of apoptosis (23, 24, 25, 26)
, alteration in the

m was studied using JC-1 dye. JC-1 is a potential-sensitive dye
that undergoes a molecular aggregation and shift in fluorescence from
green to red at high 
m. As shown in Fig. 3
, valinomycin, which is a K+ ionophore, dissipated
the 
m, as confirmed by an increase in the green fluorescence of
JC-1 and a decrease in the red fluorescence of JC-1 aggregates.
Under the same conditions, we examined the change in 
m in
MT-21-treated cells. For at least 3 h after MT-21 treatment,

m was largely retained under the condition where
cytochrome c was already released (Fig. 3)
. Further
treatment with MT-21 slightly enhanced the loss of 
m. This is a
consequence of cytochrome c loss because cytochrome
c takes part in generating 
m through the
mitochondrial respiratory chain. These observations suggest that
the release of mitochondrial cytochrome c into the cytosol
is not caused by the change in 
m.
Induction of Permeability Transition by MT-21.
CsA is known as the permeability transition pore inhibitor. Therefore,
we examined whether MT-21 induced cytochrome c release from
mitochondria via the induction of permeability transition during
apoptosis using CsA. Fig. 4A
shows that CsA caused dose-dependent inhibition of
MT-21-induced cytochrome c release from mitochondria
and the activation of caspase-9 monitoring the proteolytic
digestion of pro-caspase-3. We also examined the effect of CsA on
MT-21-induced DNA fragmentation. CsA suppressed DNA fragmentation by
MT-21 in a dose-dependent manner (Fig. 4B)
. Moreover, we
examined the effect of CsA on ROS production by MT-21. As shown in Fig. 4C
, CsA could not suppress ROS production by MT-21. These
results indicate that MT-21 induces cytochrome c release
from mitochondria via the induction of permeability transition by ROS
production during apoptosis.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 4. Inhibition of MT-21-induced apoptosis by CsA. HL-60 cells
were treated with 40 µM MT-21 for 6 h in the absence
or presence of CsA. Immunoblotting analysis was performed using
anti-cytochrome c or anti-caspase-3 antibodies
(A). Cellular DNA extracted from the cells was analyzed
by agarose gel electrophoresis and stained with ethidium bromide
(B). HL-60 cells were pretreated with or without 1 or 5
µM CsA and then treated with 40 µM MT-21.
The amount of intracellular H2O2 was measured
by flow cytometry (C).
|
|
Effect of Bcl-2 Overexpression on MT-21-induced Apoptosis.
Bcl-2 is an integral membrane protein located mainly on the outer
membrane of mitochondria and is known to prevent cell apoptosis in
response to a variety of stimuli. To evaluate the influence of Bcl-2
overexpression on MT-21-induced release of cytochrome c from
mitochondria and on apoptosis, cells transfected with vector alone
(vector cells) or with same vector containing a cDNA encoding human
Bcl-2 (Bcl-2 cells) were treated with MT-21. An increase in cytosolic
cytochrome c was induced by MT-21 in vector cells but not in
Bcl-2 cells (Fig. 5A)
. Bcl-2 expression in vector and Bcl-2 cells was confirmed
by immunoblotting with anti-Bcl-2 antibody (Fig. 5B)
.
Moreover, we carried out immunocytochemical studies of cytochrome
c distribution in MT-21-treated vector and Bcl-2 cells. The
immunostaining of untreated vector cells and Bcl-2 cells demonstrated a
punctate pattern for cytochrome c consistent with
mitochondrial localization (Fig. 5C
, Control). On
induction of apoptosis by MT-21 in vector cells, cytochrome
c lost punctate distribution and diffused throughout the
cells (Fig. 5C
, Vector/MT-21). On the other hand,
in Bcl-2 cells, MT-21 treatment failed to diffuse cytochrome
c distribution, resulting in the protection of cells from
apoptosis (Fig. 5C
, Bcl-2/MT-21). The induction
of DNA fragmentation by MT-21 was also suppressed in Bcl-2 cells (Fig. 5D)
. These results indicate that Bcl-2 inhibits
MT-21-induced apoptosis through the suppression of cytochrome
c release from the mitochondria.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5. Inhibition of MT-21-induced cytochrome c
release from mitochondria and apoptosis by overexpression of Bcl-2.
Vector and Bcl-2 cells were treated with 40 µM MT-21 for
8 h. Immunoblotting analysis was performed using anti-cytochrome
c (A) or anti-Bcl-2 antibodies
(B). C, confocal microscopy of control and MT-21
treatment on vector and Bcl-2 cells labeled with an anti-cytochrome
c antibody. D, cellular DNA extracted
from the cells was analyzed by agarose gel electrophoresis and stained
with ethidium bromide.
|
|
Release of Cytochrome c from Mitochondria by MT-21
Using a Cell-free System.
We examined whether MT-21 released cytochrome c from
mitochondria directly using a cell-free system. After preparation of
the mitochondria fraction from the cells, various concentrations of
MT-21 were added directly to the mitochondria. As shown in Fig. 6A
, MT-21 directly released cytochrome c from
isolated mitochondria, and this effect was partially suppressed by NAC
(Fig. 6B)
. NAS, the negative control of NAC, had no effect
on MT-21-induced cytochrome c release (data not shown). CsA also
inhibited MT-21-induced cytochrome c release from isolated
mitochondria (Fig. 6B)
.
Benzoyloxycabonyl-Asp-CH2O(CO)-2,6-dichlorobenzene
(Z-Asp), a synthetic inhibitor of caspases (Peptide Institute, Inc.,
Osaka, Japan), inhibited MT-21-induced apoptosis as described
previously (12)
. As shown in Fig. 6B
, Z-Asp did
not inhibit MT-21-induced cytochrome c release from isolated
mitochondria. We also examined the effect of MT-21 on mitochondria
isolated from Bcl-2 cells. Cytochrome c release from
mitochondria by MT-21 was detected on mitochondria isolated from vector
cells, but cytochrome c release was suppressed on
mitochondria isolated from Bcl-2 cells (Fig. 6C)
. Recently,
it was reported that precursors of caspase-2, -3, and -9 located on
mitochondria are released from the mitochondria to the cytosol during
the apoptotic process (27)
. Next, we examined whether
MT-21 released caspase-3 from mitochondria. As shown in Fig. 6C
, the caspase-3 precursor was released directly from
mitochondria by MT-21, and this effect was barely detected on
mitochondria isolated from Bcl-2 cells. The expression of Bcl-2 in
mitochondria isolated from Bcl-2 cells was confirmed by immunoblotting
(Fig. 6C)
. These observations indicated that MT-21
acted directly on mitochondria and induced the release of cytochrome
c and caspase-3 from mitochondria during apoptosis.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 6. Release of cytochrome c from mitochondria
by MT-21 using a cell-free system. A, mitochondria
isolated from HL-60 cells were added to the indicated concentration of
MT-21 at 37°C for 2 h. Using the supernatants obtained by
centrifugation, immunoblotting analysis was performed using
anti-cytochrome c antibodies. B,
mitochondria isolated from HL-60 cells were pretreated with 3
mM NAC or with the indicated concentration of Z-Asp and
then added to 80 nmol of MT-21. After incubation at 37°C for 2 h, immunoblotting analysis was performed as described in
A. C, mitochondria isolated from vector
or Bcl-2 cells were added to 80 nmol of MT-21 at 37°C for 2 h.
Using the supernatants obtained by centrifugation, immunoblotting
analysis was performed with anti-cytochrome c,
anti-caspase-3, or anti-Bcl-2 antibodies.
|
|
Release of Cytochrome c from Mitochondria by Other
MT Compounds.
MT-21 is a compound that has a
-lactam ring and an alkyl chain
(n-C8H17) at the N-1 position. To
determine what is necessary to release cytochrome c and
caspases from mitochondria on a structure characteristic of MT-21, we
synthesized a series of derivatives with alkyl chains of different
lengths at the N-1 or C-5 position in a
-lactam ring (Fig. 7A)
. When we examined apoptosis induction by these compounds
in HL-60 cells, only the compound (MT-21) that has an alkyl chain
(C8) at the N-1 position induced cytochrome c
release from mitochondria, activation of proteins (caspases, Krs
proteins, and JNKs), and apoptosis induction (Fig. 7
,
BE). These results suggest that an alkyl chain
(n-C8H17) at the N-1 position but
not at the C-5 position in a
-lactam ring was necessary to release
cytochrome c from mitochondria and could induce apoptosis by
acting directly on mitochondria.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 7. Induction of apoptosis by MTcompounds.
A, structure of our synthetic compounds.
B, HL-60 cells were treated with 40 µM MT
compounds for 6 h, and immunoblotting analysis was performed using
anti-cytochrome c or anti-caspase-3 antibodies. When
HL-60 cells were treated with 40 µM MT compounds for
6 h, MBP kinase activity (C), JNK activity
(D), and DNA fragmentation (E) were
analyzed as described in "Materials and Methods," respectively.
|
|
Release of Cytochrome c from Mitochondria by
Apoptosis-inducing Agents.
We examined the effect of other apoptosis-inducing agents including
MT-21, cytotrienin A, camptothecin, etoposide, paclitaxel, and
staurosporine on the release of cytochrome c from
mitochondria in HL-60 cells. As shown in Fig. 8A
, cytochrome c release into the cytosol was
detected on treatment with all of the apoptosis-inducing agents tested
here. In addition, we confirmed that treatment with the same
concentration of these apoptosis-inducing agents induced DNA
fragmentation (Fig. 8C)
. However, with the exception
of MT-21, treatment with these agents did not induce the direct release
of cytochrome c from cell-free mitochondria (Fig. 8B)
. These results suggest that cytochrome c
release from the mitochondria may be an event common to the apoptotic
program induced by antitumor agents, despite the differences in their
modes of action, and MT-21 alone is able to release cytochrome
c from mitochondria by direct action.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 8. Release of cytochrome c from mitochondria
by apoptosis-inducing agents. A, HL-60 cells were
treated with 40 µM MT-21 (4 h), 300 ng/ml cytotrienin A
(2 h), 1 µM camptothecin (6 h), 10 µM
etoposide (5 h), 0.1 µM paclitaxel (24 h), and 3
µM staurosporine (6 h), and immunoblotting analysis was
performed using anti-cytochrome c antibodies.
B, mitochondria isolated from HL-60 cells were treated
with 80 nmol of MT-21, 600 ng of cytotrienin A, 2 nmol of camptothecin,
20 nmol of etoposide, 0.2 nmol of paclitaxel, and 6 nmol of
staurosporine. After incubation at 37°C for 2 h, the
supernatants obtained by centrifugation were used to perform
immunoblotting analysis with anti-cytochrome c
antibodies. C, HL-60 cells were treated with 40
µM MT-21 (6 h), 300 ng/ml cytotrienin A (3 h), 1
µM camptothecin (8 h), 10 µM etoposide (6
h), 0.1 µM paclitaxel (30 h), and 3 µM
staurosporine (8 h). Cellular DNA extracted from the cells was analyzed
by agarose gel electrophoresis and stained with ethidium bromide.
|
|
 |
DISCUSSION
|
|---|
It is well known that most antitumor agents induce
apoptosis in cancer cells. Triggering of apoptosis by antitumor agents
involves simultaneous or subsequent activation of death receptor
systems, perturbation of mitochondrial function, and proteolytic
processing of caspases, the death effector molecules of apoptosis.
Thus, the cell death pathway may be entered at multiple sites, and most
drugs may hit various targets, although the precise molecular
mechanisms have not been characterized in detail.
The caspase cascade is activated by various stimuli including serum
withdrawal, activation of Fas, ionizing radiation, and chemical
compounds (28, 29, 30, 31, 32, 33)
. Fas activation is known to activate
the caspase cascade by interacting directly with a signaling complex on
the cell membrane (4
, 34)
. However, little is known about
the non-receptor signal transduction pathways that operate within the
cytoplasm to activate caspases. Only one apoptotic pathway in mammalian
cells is shunted through the mitochondria and involves the export of
cytochrome c to the cytoplasm (7)
. In the
present study, we found that MT-21 activated caspase-9 via cytochrome
c release, which is involved mainly in non-receptor-mediated
signaling, but did not activate caspase-8, which interacts directly
with a signaling complex on the cell membrane (Fig. 1)
.
In addition, we reported previously that ROS were involved in
MT-21-induced apoptosis in HL-60 cells because caspase cascade
activation and apoptosis were diminished by NAC (12)
. In
this study, we showed that ROS were also involved in cytochrome
c release from mitochondria during MT-21-induced apoptosis
because they were inhibited by NAC (Fig. 2C)
. Recently, the
involvement of the mitochondrial permeability transition pore in
apoptosis has been shown. The pore consists of a complex of the
mitochondrial porin channel (voltage-dependent anion channel, VDAC),
the adenine nucleotide translocase, and cyclophilin D at contact sites
between the mitochondrial outer and inner membranes. MT-21 caused
little change in 
m during apoptosis (Fig. 3)
. Therefore, it is
possible for MT-21 to act directly on mitochondria and induce
cytochrome c release from mitochondria before the change in

m; i.e., it seems that the target of MT-21 is not
VDAC.
Using CsA, which inhibits the pore formation, we found that
MT-21 released cytochrome c from mitochondria via the
mitochondrial permeability transition pore during apoptosis (Fig. 4)
.
It has been reported previously that atractyloside, which is known to
be an inhibitor of adenine nucleotide translocase, induces the
permeability transition (35)
. We compared atractyloside
with MT-21 side by side on cytochrome c-releasing and
apoptosis-inducing ability in HL-60 cells. MT-21 induced cytochrome
c release and apoptosis more rapidly and at a lower
concentration than did atractyloside (data not shown).
The initiation of the apoptotic cascades is strictly regulated because
it is most important for cell survival. Bcl-2, a gene product of
proto-oncogene bcl-2, is a widely studied negative regulator of
apoptosis (36
, 37)
. Bcl-2 is located mainly on the
membrane of mitochondria and prevents the cells from apoptosing in
response to a variety of stimuli (37)
. Previously, it was
reported that an overexpression of Bcl-2 blocked cytochrome
c release from mitochondria (9
, 38)
. In fact,
MT-21-induced cytochrome c release from mitochondria was
inhibited by overexpression of Bcl-2 (Fig. 5)
. Recently, it was
reported that precursors of caspase-2, -3, and -9 localized in both the
cytosol and mitochondria are released from mitochondria during the
apoptotic process (27)
. Using a cell-free system, MT-21
also induced the release of caspase-3 from mitochondria in the same way
as cytochrome c, and this effect was not detected on
mitochondria isolated from the cells overexpressing Bcl-2. Thus, the
direct release of cytochrome c or caspases from mitochondria
by MT-21 was regulated by Bcl-2. It is therefore acknowledged that the
release of cytochrome c or caspases from mitochondria by
MT-21 was not a leak caused by the damage against mitochondria, and we
suspect that MT-21 activates the mechanism releasing mitochondrial
proteins from mitochondria.
In this study, we showed that ROS were involved in the release of
cytochrome c from mitochondria during MT-21-induced
apoptosis because MT-21-induced apoptosis is inhibited by NAC.
However, MT-21-induced release of cytochrome c in
mitochondria isolated from the cells was slightly inhibited by NAC
(Fig. 6B)
. Considering these results, we suspect that MT-21
induces ROS production in both cytosol and mitochondria. Because the
mechanism by which ROS production is able to activate the caspase
cascade during MT-21-induced apoptosis has not yet been clarified, the
elucidation of this mechanism will be necessary in the future.
MT-21 is a compound which has a
-lactam ring and an alkyl chain
(n-C8H17) at the N-1 position. To
determine what is necessary to release the cytochrome c and
caspases from mitochondria on a structure characteristic of MT-21, we
synthesized a series of derivatives with alkyl chains of different
lengths at the N-1 position in a
-lactam ring. When we examined the
apoptosis induction by these compounds in HL-60 cells, only MT-21,
which has an alkyl chain (C8) at the N-1 position, induced
cytochrome c release from mitochondria, the activation of
proteins (caspases, Krs proteins, and JNKs), and apoptosis induction
(Fig. 7)
. Moreover, compounds with an alkyl chain at the C-5 position
failed to induce apoptosis (Fig. 7)
. These results suggest that an
alkyl chain (n-C8H17) at the N-1
position but not the C-3 position in a
-lactam ring was necessary to
release cytochrome c from mitochondria and could induce
apoptosis by acting directly on mitochondria.
Recently, in response to the activation of cell surface death
receptors such as Fas, it was shown that a Bcl-2-interacting protein,
BID, induced the release of cytochrome c from mitochondria
by a caspase-dependent mechanism (39, 40, 41, 42)
. BID is
cleavaged by caspase-8, and the cleavaged form of BID translocates to
the mitochondrial membrane, where it is a potent inducer of cytochrome
c release. Because MT-21 caused no activation of
caspase-8, BID was considered to have no impact on MT-21-induced
apoptosis. On the other hand, it was reported that
Ca2+ and Bax released cytochrome c
from mitochondria by a caspase-independent mechanism (43
, 44)
. However, HL-60 cells already express a constant level of
Bax, and MT-21 caused no change in the amount of Bax (data not
shown). MT-21 released cytochrome c from mitochondria by a
Bax-independent mechanism. Moreover, apoptosis-inducing agents that are
able to induce cytochrome c release from mitochondria such
as camptothecin, etoposide, paclitaxel, staurosporine, and cytotrienin
A could not directly release cytochrome c from the cell-free
mitochondria (Fig. 8)
. Han et al. reported that
staurosporine as well as Fas induced cytochrome c release
from mitochondria via BID (45)
. Recently, several groups
have reported anticancer agents that exert a direct effect on
mitochondria, such as betulinic acid, lonidamine, CD437
(6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid),
arsenite, and the peptide motif KLAKKLAKKLAKKLAK (46, 47, 48, 49)
.
However, all of these agents induce apoptosis by provoking a disruption
of the mitochondrial transmembrane potential (
m). MT-21 provoked
no change in 
m. These results suggest that MT-21 is the
apoptosis-inducing compound that is able to induce the direct release
of cytochrome c from mitochondria both in situ
and in vitro, and this is unprecedented because MT-21 has no
effect on 
m.
 |
ACKNOWLEDGMENTS
|
|---|
MT compounds and U937 cells transfected with Bcl-2 were a
generous gift from Taisho Pharmaceutical Co., Ltd. (Tokyo, Japan) and
Dr. K. Nakaya (Showa University, Tokyo, Japan), respectively.
 |
FOOTNOTES
|
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported in part by a grant for multibioprobes
(RIKEN) and a grant from the Ministry of Education, Science, Sports and
Culture, Japan. M. W. and K. M. are supported by a Special
Postdoctoral Researchers Program, Science Technology Agency. 
2 To whom requests for reprints should be
addressed, at Antibiotics Laboratory, Riken Institute, Hirosawa 2-1,
Wako-shi, Saitama 351-0198, Japan. Phone: 81-48-467-9541; Fax:
81-48-462-4669; E-mail: antibiot{at}postman.riken.go.jp 
3 The abbreviations used are: JNK,
c-Jun-NH2-terminal kinase; MBP, myelin basic protein; PMSF,
phenylmethylsulfonyl fluoride; TBS, 20 mM Tris-HCl buffer
(pH 7.4) containing 0.15 M NaCl; DCFH-DA,
dichlorodihydrofluorescein diacetate; ROS, reactive oxygen species;
NAC, N-acetylcysteine; NAS,
N-acetylserine; CsA, cyclosporin A. 
Received 12/28/99.
Accepted 7/20/00.
 |
REFERENCES
|
|---|
-
Nicholson W. D., Ali A., Thornberry N. A., Vaillancourt J. P., Ding C. K., Gallant M., Gareau Y., Griffin P. R., Labelle M., Lazebnik Y. A., Munday N. A., Raju S. M., Smulson M. E., Yamin T. T., Yu V. L., Miller D. K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature (Lond.), 376: 37-43, 1995.[Medline]
-
Cohen G. M. Caspases: the executioners of apoptosis. Biochem. J., 326: 1-16, 1997.
-
Chinnaiyan A. M., ORourke K., Tewari M., Dixit V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 81: 505-512, 1995.[Medline]
-
Boldin M. P., Goncharov T. M., Goltsev Y. V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo1-and TNF receptor-induced cell death. Cell, 85: 803-815, 1996.[Medline]
-
Yang X., Chang H. Y., Baltimore D. Autoproteolytic activation of pro-caspases by oligomerization. Mol. Cell, 1: 319-325, 1998.[Medline]
-
Li P., Nijhawan D., Budihardjo I., Srinivasula S. M., Ahmad M., Alnemri E. S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-490, 1997.[Medline]
-
Liu X., Kim C. N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 86: 147-157, 1996.[Medline]
-
Zou H., Henzel W. J., Liu X., Lutschg A., Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90: 405-413, 1997.[Medline]
-
Yang J., Liu X., Bhalla K., Kim C. N., Ibrado A. M., Cai J., Peng T., Jones D. P., Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (Washington DC), 275: 1129-1132, 1997.[Abstract/Free Full Text]
-
Gonzales D. H., Neupert W. Biogenesis of mitochondrial c-type cytochromes. J. Bioenerg. Biomembr., 22: 753-768, 1990.[Medline]
-
Muzio M., Salvesen G. S., Dixit V. M. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J. Biol. Chem., 272: 2952-2956, 1997.[Abstract/Free Full Text]
-
Watabe M., Kakeya H., Osada H. Requirement of protein kinase (Krs/MST) activation for MT-21-inducing apoptosis. Oncogene, 18: 5211-5220, 1999.[Medline]
-
Creasy C. L., Chernoff J. Cloning and characterization of a human protein kinase with homology to Ste20. J. Biol. Chem., 270: 21695-21700, 1995.[Abstract/Free Full Text]
-
Taylor L. K., Wang H-C. R., Erikson R. L. Newly identified stress-responsive protein kinases, Krs-1 and Krs-2. Proc. Natl. Acad. Sci. USA, 93: 10099-10104, 1996.[Abstract/Free Full Text]
-
Kakeya H., Onose R., Osada H. Caspase-mediated activation of a 36-kDa myelin basic protein kinase during anticancer drug-induced apoptosis. Cancer Res., 58: 4888-4894, 1998.[Abstract/Free Full Text]
-
Kakeya H., Zhang H-P., Kobinata K., Onose R., Onozawa C., Kudo T., Osada H. Cytotrienin A, a novel apoptosis inducer in human leukemia HL-60 cells. J. Antibiot. (Tokyo), 50: 370-372, 1997.[Medline]
-
Zhang H-P., Kakeya H., Osada H. Novel triene-ansamycins, cytotrienin A and B, inducing apoptosis on human leukemia HL-60 cells. Tetrahedron Lett., 38: 1789-1792, 1997.
-
Graves J. D., Gotoh Y., Draves K. E., Ambrose D., Han D. K. M., Wright M., Chernoff J., Clark E. A., Krebs E. G. Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J., 17: 2224-2234, 1998.[Medline]
-
Lee K. K., Murakawa M., Nishida E., Tsubuki S., Kawashima K., Sakamaki K., Yonehara S. Proteolitic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis. Oncogene, 16: 3029-3037, 1998.[Medline]
-
Kakeya H., Onozawa C., Sato M., Arai K., Osada H. Neuritogenic effect of epolactaene derivatives on human neuroblastoma cells which lack high-affinity nerve growth factor receptors. J. Med. Chem., 40: 391-394, 1997.[Medline]
-
Jürgensmeier J. M., Xie Z., Deveraux Q., Ellerby L., Bredesen D., Reed J. C. Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl. Acad. Sci. USA, 95: 4997-5002, 1998.[Abstract/Free Full Text]
-
Watabe M., Nakajo S., Yoshida T., Kuroiwa Y., Nakaya K. Treatment of U937 cells with bufalin induces the translocation of casein kinase 2 and modulates the activity of topoisomerase II prior to the induction of apoptosis. Cell Growth Differ., 8: 871-879, 1997.[Abstract]
-
Reed J. C. Cytochrome c: cant live with itcant live without it. Cell, 91: 559-562, 1997.[Medline]
-
Van der Heiden M. G., Chandel N. S., Williamson E. K., Schumacker P. T., Thompson C. B. Bcl-XL regulates the membrane potential and volume homeostasis of mitochondria. Cell, 91: 627-637, 1997.[Medline]
-
Kroemer G., Dallaporta B., Resche-Rigon M. The mitochondria death/life regulator in apoptosis and necrosis. Annu. Rev. Physiol., 60: 619-642, 1998.[Medline]
-
Rosse T., Olivier R., Monney L., Rager M., Conus S., Fellay I., Jansen B., Borner C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature (Lond.), 391: 496-499, 1998.[Medline]
-
Susin S. A., Lorenzo H. K., Zamzami N., Marzo I., Brenner C., Larochette N., Prevost M., Alzari P. M., Kroemer G. Mitochondria release of caspase-2 and -9 during the apoptotic process. J. Exp. Med., 189: 381-393, 1999.[Abstract/Free Full Text]
-
Darmon A. J., Ley T. J., Nicholson D. W., Bleackley R. C. Cleavage of cpp32 by granzyme B represents a critical role for granzyme B in the induction of target cell DNA fragmentation. J. Biol. Chem., 271: 21709-21712, 1996.[Abstract/Free Full Text]
-
Chinnaiyan A. M., Orth K., ORourke K., Duan H., Poirier G. G., Dixit V. M. Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3- like apoptotic proteases. J. Biol. Chem., 271: 4573-4576, 1996.[Abstract/Free Full Text]
-
Dubrez L., Savoy I., Hamman A., Solary E. Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J., 15: 5504-5512, 1996.[Medline]
-
Hasegawa J., Kamada S., Kamiike W., Shimizu S., Imazu T., Matsuda H., Tsujimoto Y. Involvement of CPP32/Yama (-like) proteases in Fas-mediated apoptosis. Cancer Res., 56: 1713-1718, 1996.[Abstract/Free Full Text]
-
Jacobson M. D., Weil M., Raff M. C. Role of Ced-3/ICE-family of proteases in staurosporine-induced programmed cell death. J. Cell Biol., 133: 1041-1051, 1996.[Abstract]
-
Schlegel J., Peter I., Orrenius S., Miller D. K., Thornberry N. A., Yamin T. T., Nicholson D. W. CPP32/apopain is a key interleukin 1ß-converting enzyme-like protease involved in Fas-mediated apoptosis. J. Biol. Chem., 271: 1841-1844, 1996.[Abstract/Free Full Text]
-
Muzio M., Chinnaiyan A. M., Kischkel F. C., ORourke K., Shevchenko A., Scaffidi C., Bretz J. D., Zhang M., Ni J., Gentz R., Mann M., Krammer P. H., Peter M. E., Dixit V. M. FLICE, a novel FADD-homologous ICE/CED-3-like proteases, is recruited to the CD95 (Fas/Apo-1) death-inducing signaling complex. Cell, 85: 817-827, 1996.[Medline]
-
Vancompernolle K., Van Herreweghe F., Pynaert G., Vav de Craen M., De Vos K., Tonny N., Sterling A., Fiers W., Vandenabeele P., Grooten J. Atractyloside-induced release of cathepsin B, a protease with caspase-processing activity. FEBS Lett., 438: 150-158, 1998.[Medline]
-
Hockenbery D., Nunez G., Milliman C., Schreiber R. D., Korsmeyer S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334-338, 1990.[Medline]
-
Reed J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1995.[Free Full Text]
-
Kluck R. M., Bossy-Wetzel E., Green D. R., Newmeyer D. D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science (Washington DC), 275: 1132-1136, 1997.[Abstract/Free Full Text]
-
Wang K., Yin X-M., Chao D. T., Milliman C. L., Korsmeyer S. BID: a novel BH3 domain-only death agonist. Genes Dev., 10: 2859-2869, 1996.[Abstract/Free Full Text]
-
Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94: 481-490, 1998.[Medline]
-
Li H., Zhu H., Xu C., Yuan J. Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94: 491-501, 1998.[Medline]
-
Gross A., Yin X-M., Wang K., Wei M. C., Jockel J., Milliman C., Erdjument-Bromage H., Tempst P., Korsmeyer S. J. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while Bcl-XL prevents this release but not tumor necrosis factor- R1/Fas death. J. Biol. Chem., 274: 1156-1163, 1999.[Abstract/Free Full Text]
-
Green D., Reed J. Mitochondria and apoptosis. Science (Washington DC), 281: 1309-1312, 1998.[Abstract/Free Full Text]
-
Murphy A., Fiskum G., Beal M. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J. Cereb. Blood Flow Metab., 19: 231-245, 1999.[Medline]
-
Han Z., Bhalla K., Pantazis P., Hendrickson E. A., Wyche J. H. Cif (cytochrome c efflux-inducing factor) activity is regulated by Bcl-2 and caspases and correlates with the activation of Bid. Mol. Cell. Biol., 19: 1381-1389, 1999.[Abstract/Free Full Text]
-
Fulda S., Scaffidi C., Susin S. A., Krammer P. H., Kroemer G., Peter M. E., Debatin K. M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem., 273: 33942-33948, 1998.[Abstract/Free Full Text]
-
Ravagnan L., Marzo I., Costantini P., Susin S. A., Zamzami N., Petit P. X., Hirsch F., Goulbern M., Poupon M. F., Miccoli L., Xie Z., Reed J. C., Kroemer G. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene, 18: 2537-2546, 1999.[Medline]
-
Marchetti P., Zamzami N., Joseph B., Schraen-Maschke S., Mereau-Richard C., Costantini P., Metivier D., Susin S. A., Kroemer G., Formstecher P. The novel retinoid 6-[3-(1- adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res., 59: 6257-6266, 1999.[Abstract/Free Full Text]
-
Larochette N., Decaudin D., Jacotot E., Brenner C., Marzo I., Susin S. A., Zamzami N., Xie Z., Reed J., Kroemer G. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp. Cell Res., 249: 413-421, 1999.[Medline]
This article has been cited by other articles:

|
 |

|
 |
 
M. Watabe and T. Nakaki
Mitochondrial Complex I Inhibitor Rotenone Inhibits and Redistributes Vesicular Monoamine Transporter 2 via Nitration in Human Dopaminergic SH-SY5Y Cells
Mol. Pharmacol.,
October 1, 2008;
74(4):
933 - 940.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Watabe, K. Aoyama, and T. Nakaki
A Dominant Role of GTRAP3-18 in Neuronal Glutathione Synthesis
J. Neurosci.,
September 17, 2008;
28(38):
9404 - 9413.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Watabe and T. Nakaki
Mitochondrial Complex I Inhibitor Rotenone-Elicited Dopamine Redistribution from Vesicles to Cytosol in Human Dopaminergic SH-SY5Y Cells
J. Pharmacol. Exp. Ther.,
November 1, 2007;
323(2):
499 - 507.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Watabe, K. Aoyama, and T. Nakaki
Regulation of Glutathione Synthesis via Interaction between Glutamate Transport-Associated Protein 3-18 (GTRAP3-18) and Excitatory Amino Acid Carrier-1 (EAAC1) at Plasma Membrane
Mol. Pharmacol.,
November 1, 2007;
72(5):
1103 - 1110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-C. Lee, C.-H. Lee, C.-L. Su, C.-W. Huang, H.-S. Liu, C.-N. Lin, and S.-J. Won
Justicidin A decreases the level of cytosolic Ku70 leading to apoptosis in human colorectal cancer cells
Carcinogenesis,
October 1, 2005;
26(10):
1716 - 1730.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Watabe and T. Nakaki
Rotenone Induces Apoptosis via Activation of Bad in Human Dopaminergic SH-SY5Y Cells
J. Pharmacol. Exp. Ther.,
December 1, 2004;
311(3):
948 - 953.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kondoh, I. Suzuki, M. Sato, F. Nagashima, S. Simizu, M. Harada, M. Fujii, H. Osada, Y. Asakawa, and Y. Watanabe
Kaurene Diterpene Induces Apoptosis in Human Leukemia Cells Partly through a Caspase-8-Dependent Pathway
J. Pharmacol. Exp. Ther.,
October 1, 2004;
311(1):
115 - 122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Watabe, K. Hishikawa, A. Takayanagi, N. Shimizu, and T. Nakaki
Caffeic Acid Phenethyl Ester Induces Apoptosis by Inhibition of NF{kappa}B and Activation of Fas in Human Breast Cancer MCF-7 Cells
J. Biol. Chem.,
February 13, 2004;
279(7):
6017 - 6026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Machida, Y. Hayashi, and H. Osada
A Novel Adenine Nucleotide Translocase Inhibitor, MT-21, Induces Cytochrome c Release by a Mitochondrial Permeability Transition-independent Mechanism
J. Biol. Chem.,
August 16, 2002;
277(34):
31243 - 31248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Smith, A. Kazi, L. Smith, T. E. Long, B. Heldreth, E. Turos, and Q. P. Dou
A Novel beta -Lactam Antibiotic Activates Tumor Cell Apoptotic Program by Inducing DNA Damage
Mol. Pharmacol.,
June 1, 2002;
61(6):
1348 - 1358.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Chen, D. L. Kramer, P. Diegelman, S. Vujcic, and C. W. Porter
Apoptotic Signaling in Polyamine Analogue-treated SK-MEL-28 Human Melanoma Cells
Cancer Res.,
September 1, 2001;
61(17):
6437 - 6444.
[Abstract]
[Full Text]
[PDF]
|
 |
|